<DOC>
	<DOC>NCT02588755</DOC>
	<brief_summary>The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection</brief_summary>
	<brief_title>TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Male or female patients &gt; 18 years and &lt;=70 years of age. Pathological evidence of ICC Tumors can be completely resected. Criteria of liver function: Child AB level, serum bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. Patients who can understand this trial and have signed information consent. Tumors can not be resected . Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of Intrahepatic cholangiocarcinoma. Patients with a medical history of other malignant tumors. Subjects participating in other clinical trials. Liver function:Child C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chemoembolization</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Tegafur</keyword>
</DOC>